A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML).
• Tyrosine kinase inhibitors (TKI) targeting FLT3 have shown limited clinical success.
• Endogenous plasma proteins can inhibit TKI activity, reducing drug efficacy.

Purpose of the Study:

• To investigate the inhibitory effect of alpha-1-acid glycoprotein (AGP) on FLT3 TKI.
• To evaluate mifepristone as a means to overcome AGP-mediated TKI inhibition.
• To explore strategies for enhancing TKI efficacy in AML.

Main Methods:

• Characterization of plasma protein binding of staurosporine-derivative TKI (STS-TKI) by AGP.
• In vitro assessment of STS-TKI anti-proliferative activity in FLT3-ITD-dependent cells with and without human AGP.
• In vivo studies using a mouse model to evaluate mifepristone's effect on TKI activity under AGP inhibition.

Main Results:

• Human AGP significantly inhibited the anti-proliferative activity of STS-TKI, with IC50 values exceeding clinically achievable concentrations.
• Non-human plasma did not exhibit this inhibitory effect.
• Mifepristone, due to its high AGP affinity, restored TKI activity, achieving clinically effective IC50 values.
• In a mouse model, mifepristone reversed AGP-induced inhibition of midostaurin activity.

Conclusions:

• Plasma protein binding, specifically by AGP, is a significant mechanism for FLT3 TKI inhibition in AML.
• Co-administration with mifepristone can overcome AGP-mediated inhibition, enhancing TKI efficacy.
• These findings suggest combinatorial approaches to improve TKI therapy for AML and guide the development of novel small-molecule agents targeting drug-protein interactions.